ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the successful approval for the full circulation listing of its H shares on The Stock Exchange of Hong Kong Limited, involving a conversion of 120,463,260 unlisted shares. This move will result in 11 participating shareholders holding approximately 34.52% of the total issued H Shares, with the largest shareholder, Dr. Tian Wenzhi, holding a 10.05% stake.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
